MAPT and Insulin resistance: Tau pathology has emerged as a trigger of insulin resistance and insulin deficiency in the brain and peripheral tissues, and it is suggested to be an early event in the pathogenesis of AD and other tauopathies, representing a promising therapeutic target capable of interfering with disease progression.